TY - JOUR
T1 - Incremental Versus Standard (Full-Dose) Peritoneal Dialysis
AU - Cheetham, Melissa S.
AU - Cho, Yeoungjee
AU - Krishnasamy, Rathika
AU - Jain, Arsh K.
AU - Boudville, Neil
AU - Johnson, David W.
AU - Huang, Louis L.
N1 - Funding Information:
MSC has received travel support from Amgen and is supported by a Queensland Advancing Clinical Research Fellowship. AKJ has received consultancy fees, research grants, speaker’s honoraria, and/or travel sponsorship from Baxter Healthcare and AWAK Technologies. NB has received consultancy fees, research grants, speaker’s honoraria, or travel sponsorship from Baxter Healthcare, Vifor Pharmaceuticals, AstraZeneca, Roche, and Amgen. DWJ has received consultancy fees, research grants, speaker’s honoraria, and travel sponsorships from Baxter Healthcare and Fresenius Medical Care; consultancy fees from AstraZeneca, Bayer, and AWAK; speaker’s honoraria from Ono and BI & Eli Lilly; and travel sponsorships from Ono and Amgen; and is a current recipient of an Australian National Health and Medical Research Council Leadership Investigator Grant. YC has received research grants and speaker’s honoraria from Baxter Healthcare and Fresenius Medical Care. All the other authors declared no competing interests.
Publisher Copyright:
© 2021 International Society of Nephrology
PY - 2022/2
Y1 - 2022/2
N2 - Incremental peritoneal dialysis (PD), defined as less than “standard dose” PD prescription, has a number of possible benefits, including better preservation of residual kidney function (RKF), reduced risk of peritonitis, lower peritoneal glucose exposure, lesser environmental impact, and reduced costs. Patients commencing PD are often new to kidney replacement therapy and possess substantial RKF, which may allow safe delivery of an incremental prescription, often in the form of lower frequency or duration of PD. This has the potential to help improve quality of life (QOL) and life participation through reducing time requirements and burden of treatment. Alternatively, incremental PD could potentially contribute to reduced small solute clearance, fluid overload, or patient reluctance to increase dialysis prescription when later needed. This review discusses the definition, rationale, uptake, potential advantages and disadvantages, and clinical trial evidence pertaining to the use of incremental PD.
AB - Incremental peritoneal dialysis (PD), defined as less than “standard dose” PD prescription, has a number of possible benefits, including better preservation of residual kidney function (RKF), reduced risk of peritonitis, lower peritoneal glucose exposure, lesser environmental impact, and reduced costs. Patients commencing PD are often new to kidney replacement therapy and possess substantial RKF, which may allow safe delivery of an incremental prescription, often in the form of lower frequency or duration of PD. This has the potential to help improve quality of life (QOL) and life participation through reducing time requirements and burden of treatment. Alternatively, incremental PD could potentially contribute to reduced small solute clearance, fluid overload, or patient reluctance to increase dialysis prescription when later needed. This review discusses the definition, rationale, uptake, potential advantages and disadvantages, and clinical trial evidence pertaining to the use of incremental PD.
KW - incremental dialysis
KW - patient-centered care
KW - peritoneal dialysis
KW - personalized medicine
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85121709026&partnerID=8YFLogxK
U2 - 10.1016/j.ekir.2021.11.019
DO - 10.1016/j.ekir.2021.11.019
M3 - Review Article
C2 - 35155856
AN - SCOPUS:85121709026
SN - 2468-0249
VL - 7
SP - 165
EP - 176
JO - Kidney International Reports
JF - Kidney International Reports
IS - 2
ER -